Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.34 |
| ▸ | S100A4 | P26447 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.34 |
| ▸ | RORB | Q92753 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL904675 | 0.78 | TRPV1 (0.44) | CNR2ALDH1A1TRPV1CYP2A6S100A4 | |
| SCHEMBL904498 | 0.77 | TRPV1 (0.46) | TRPV1 | |
| SCHEMBL4188475 | 0.76 | CNR2 (0.55) | CNR2TRPV1CYP2A6 | |
| SCHEMBL19385269 | 0.75 | CYP2A6 (0.45) | ALDH1A1CYP2A6MEN1KMT2A | |
| SCHEMBL30893537 | 0.74 | KCNJ1 (0.44) | ALDH1A1CYP2A6MEN1KMT2A | |
| SCHEMBL16761877 | 0.74 | KCNJ1 (0.44) | ALDH1A1CYP2A6MEN1KMT2A | |
| SCHEMBL29893944 | 0.74 | KCNJ1 (0.44) | ALDH1A1CYP2A6MEN1KMT2A | |
| SCHEMBL4182641 | 0.73 | CNR2 (0.49) | CNR2ALDH1A1TRPV1RORBMEN1 | |
| SCHEMBL4152602 | 0.73 | CNR2 (0.35) | CNR2ALDH1A1 | |
| SCHEMBL16761875 | 0.73 | CYP2A6 (0.56) | ALDH1A1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621915-B1 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAE WOONG PHARMA (KR) | 2016-04-20 | — | — | EP | claimed |
| US-9040572-B2 | Method of preparing benzoimidazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-26 | — | — | US | claimed |
| US-20130231477-A1 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-09-05 | — | — | US | claimed |
| EP-2621915-A2 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | Daewoong Pharmaceutical Co., Ltd (KR) | 2013-08-07 | — | — | EP | claimed |
| WO-2012044043-A2 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2012-04-05 | — | — | WO | claimed |
| EP-2621915-B1 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAE WOONG PHARMA (KR) | 2016-04-20 | — | — | EP | disclosed |
| EP-2621915-B1 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAE WOONG PHARMA (KR) | 2016-04-20 | — | — | EP | disclosed |
| US-9040572-B2 | Method of preparing benzoimidazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-26 | — | — | US | disclosed |
| US-9040572-B2 | Method of preparing benzoimidazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-26 | — | — | US | disclosed |
| US-9040572-B2 | Method of preparing benzoimidazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-26 | — | — | US | disclosed |
| US-20130231477-A1 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-09-05 | — | — | US | disclosed |
| US-20130231477-A1 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-09-05 | — | — | US | disclosed |
| US-20130231477-A1 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-09-05 | — | — | US | disclosed |
| EP-2621915-A2 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | Daewoong Pharmaceutical Co., Ltd (KR) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012044043-A2 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012044043-A2 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231477-A1 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | BRD1, BRD4, VAT1 | CNR2 382/4885ALDH1A1 441/4885TRPV1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.